Integrated genetic and pharmacologic interrogation of rare cancers

Identifying therapeutic targets in rare cancers remains challenging due to the paucity of established models to perform preclinical studies. As a proof-of-concept, we developed a patient-derived cancer cell line, CLF-PED-015-T, from a paediatric patient with a rare undifferentiated sarcoma. Here, we...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Autores principales: Hong, Andrew L., Tseng, Yuen-Yi, Cowley, Glenn S., Jonas, Oliver, Cheah, Jaime H., Kynnap, Bryan D., Doshi, Mihir B., Oh, Coyin, Meyer, Stephanie C., Church, Alanna J., Gill, Shubhroz, Bielski, Craig M., Keskula, Paula, Imamovic, Alma, Howell, Sara, Kryukov, Gregory V., Clemons, Paul A., Tsherniak, Aviad, Vazquez, Francisca, Crompton, Brian D., Shamji, Alykhan F., Rodriguez-Galindo, Carlos, Janeway, Katherine A., Roberts, Charles W. M., Stegmaier, Kimberly, van Hummelen, Paul, Cima, Michael J., Langer, Robert S., Garraway, Levi A., Schreiber, Stuart L., Root, David E., Hahn, William C., Boehm, Jesse S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4917959/
https://ncbi.nlm.nih.gov/pubmed/27329820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11987
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares